Background
==========

Allergic rhinitis (AR) is poorly controlled. Treated patients, even those on multiple therapies still experience symptoms. In a UK survey, 70.5% of moderate-to-severe AR patients took ≥2 medications (either Rx or over the counter) in an attempt to achieve better and faster symptom relief.

Aim
===

To explore the extent of co-prescribing by UK general practitioners (GPs) during the hay-fever season in patients with seasonal AR (SAR), perennial AR (PAR), and comorbid asthma.

Method
======

A retrospective database study using the Optimum Patient Care Research Database consisting of data extracted from GP records supplemented with patient-reported outcomes from questionnaires. Patients included in the analysis had a recorded AR diagnosis and ≥1 AR therapy scripts during 1st March 2010 to 31st August 2010.

Results
=======

In all, 22,381 AR patients were included. Results are summarized in the table.

  --------------------------------------------------------------------------------------------------------------------------
  1st March 2010 to 31st August 2010                                                                       
  ------------------------------------ --------------------- -------------------------- ------------------ -----------------
                                       SAR (n=16187)         PAR (n=6194)                                  

                                                                                                           

  Therapy, n (%)                       **Season Start**      **Season End**             **Season Start**   **Season End**

                                                                                                           

  Single therapy                       10776 (65.5)          8850 (54.7)                4764 (76.9)        2974 (48.0)

                                                                                                           

  Dual therapy                         3782 (23.4)           5213 (32.2)                1172 (18.9)        2445 (39.5)

                                                                                                           

  Triple therapy                       1615 (10.0)           2062 (12.7)                244 (3.9)          694 (11.2)

                                                                                                           

  Quadruple therapy                    24 (0.1)              62 (0.4)                   14 (0.2)           77 (1.2)

                                                                                                           

  5 therapies                          0 (0.0)               0 (0.0)                    0 (0.0)            4 (0.1)

                                                                                                           

  **Total on combinations**            **5421 (33.5)**       **7337 (45.3)**            **1430 (23.0)**    **3220 (52.0)**

                                                                                                           

  **Season End, n (%)**                **Asthma (n=8787)**   **Non Asthma (n=13594)**                      

                                                                                                           

                                       SAR                   PAR                        SAR                PAR

                                                                                                           

  **Combination therapy**\             \                     \                          \                  \
  Start of season\                     1536 (24.6)\          780 (23.9)\                3885 (36.4)\       650 (22.2)\
  End of season                        2296 (41.6)           1805 (55.2)                5041 (47.2)        1415 (48.4)
  --------------------------------------------------------------------------------------------------------------------------

Conclusion
==========

In contrast to previous surveys, these data relate to prescriptions only and show a high level of co-prescribing behavior among UK GPs. There was a significant shift to combination therapy during the season, particularly for PAR patients, with strong co-prescription evident regardless of asthma co-morbidity. These data indicate that (i) UK GPs are aware that current therapy provides insufficient symptom relief, (ii) that AR is a costly disease to treat requiring several GP visits over the season for therapy modification and (iii) there is a need for an AR therapy which provides more complete symptom relief.
